145 suspended. 145 Phase 2, 53 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 145 | Suspended 145 |
| Phase 1 | 53 | Suspended 53 |
| Phase 3 | 7 | Suspended 7 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC Rintatolimod - Pancreatic Cancer | Phase 2 | Suspended | AIM ImmunoTech Inc. | 90 | 2027-08-01 | 2026-08-19 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1 / Phase 2 | Suspended | Washington University School of Medicine | 68 | 2026-11-30 | 2026-10-30 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-11 | 2026-11-06 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-11 | 2026-11-06 |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-11-11 | 2026-11-06 |
| Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) Taletrectinib - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Suspended | Megan Kruse, MD | 61 | 2026-10-01 | 2026-06-05 |
| Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) Magtrace - Ductal Carcinoma in Situ | Phase 2 | Suspended | University of Florida | 30 | 2026-10-01 | 2026-09-11 |
| Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC Olomorasib, Pembrolizumab - Lung Cancer, Lung Cancer (NSCLC) | Phase 2 | Suspended | UNC Lineberger Comprehensive Cancer Center | 60 | 2026-10-01 | 2026-08-28 |
| TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer TGFBR2 KO CAR27/IL-15 NK cells - Pancreatic Cancer | Phase 1 / Phase 2 | Suspended | M.D. Anderson Cancer Center | 37 | 2026-05-26 | 2026-11-03 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia Blinatumomab - Phase 2 Study, Blinatumomab | Phase 2 | Suspended | M.D. Anderson Cancer Center | 40 | 2026-04-21 | 2026-10-08 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.) - Metastatic Colorectal Cancer, Oligometastatic Disease | Phase 2 | Suspended | UMC Utrecht | 93 | 2025-12-01 | 2025-03-28 |
| Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer Trifluridine/tipiracil, Oxaliplatin - Biliary Tract Cancer, Biliary Tract Neoplasms | Phase 2 | Suspended | Case Comprehensive Cancer Center | 27 | 2025-12-01 | 2026-10-20 |
| SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma Systemic therapy, Radiotherapy - Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Suspended | Shandong Cancer Hospital and Institute | 184 | 2025-11-30 | 2026-10-15 |
| HEARTS Trial for Thoracic Cancers MRgART, LINAC - Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III | Phase 2 | Suspended | University of Wisconsin, Madison | 60 | 2025-10-08 | 2026-10-30 |
Showing 20 of 145. Sign in to see all of them.
Pancreatic Neoplasms (11) · Carcinoma, Non-Small-Cell Lung (10) · Colorectal Neoplasms (9) · Leukemia, Myeloid, Acute (9) · Melanoma (8) · Myelodysplastic Syndromes (7) · Prostatic Neoplasms (7) · Stomach Neoplasms (7) · Breast Neoplasms (6) · Glioblastoma (6) · Multiple Myeloma (6) · Neoplasm Metastasis (6) · Carcinoma, Hepatocellular (5) · Lung Neoplasms (5)
Neoplasms by Site (90) · Neoplasms by Histologic Type (87) · Digestive System Diseases (40) · Digestive System Neoplasms (40) · Neoplasms, Glandular and Epithelial (39) · Hemic and Lymphatic Diseases (36) · Carcinoma (26) · Gastrointestinal Diseases (24) · Hematologic Diseases (24) · Immune System Diseases (24) · Immunoproliferative Disorders (24) · Lymphoproliferative Disorders (24) · Gastrointestinal Neoplasms (23) · Lymphatic Diseases (20)
Magnetic Resonance Spectroscopy (15) · Specimen Handling (12) · Biopsy (9) · Nivolumab (7) · pembrolizumab (7) · Bevacizumab (6) · Cisplatin (6) · Cyclophosphamide (6) · Docetaxel (5) · Gemcitabine (5) · X-Rays (5) · Capecitabine (4) · Doxorubicin (4) · Radiosurgery (4) · Vincristine (4)
National Cancer Institute (NCI) (9) · City of Hope Medical Center (5) · M.D. Anderson Cancer Center (5) · Hokkaido Gastrointestinal Cancer Study Group (3) · Thomas Jefferson University (3) · Case Comprehensive Cancer Center (2) · Centre Leon Berard (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Mayo Clinic (2) · Northwestern University (2) · Oshadi Drug Administration (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · The Clatterbridge Cancer Centre NHS Foundation Trust (2) · Tianjin Medical University Cancer Institute and Hospital (2) · University of California, Davis (2)
United States (88) · China (21) · France (9) · Canada (4) · Germany (4) · Italy (4) · Japan (4) · Spain (4) · Israel (3) · United Kingdom (3) · Australia (2) · Netherlands (2) · Singapore (2) · Switzerland (2) · Austria (1)
David S Schrump, M.D. (2) · Masahiro Asaka, MD, PhD (2) · Abdulrahman Jazieh, MD/MPH (1) · Abhay Singh, MD, MPH (1) · Alan Jeppsen, MD (1) · Alexandre V. Hirayama, MD (1) · Amandeep Salhotra (1) · Andrew Poklepovic, MD (1) · Anna Bar (1) · Ardaman S. Shergill, MD (1) · Ari J Rosenberg (1) · Arvind Nageshwara Dasaru, MD (1) · Benjamin D Smith (1) · Bently Doonan, MD, MS (1) · Cameron Gaskill, MD (1)
PMID 19284416, PMID 20510306, PMID 24006012, PMID 24635869, PMID 26094080, PMID 27736729, PMID 28069018, PMID 29800971, PMID 31182448, PMID 32557715, PMID 32871584, PMID 33329935, PMID 33394722, PMID 33593311, PMID 34482636, PMID 34717797, PMID 36216274, PMID 36331676, PMID 36755288, PMID 36765881, PMID 38022532, PMID 39390760, PMID 40706069, PMID 40915303, PMID 41117344, PMID 42719952, PMID 8625188
P30CA033572 (4), U10CA180821 (3), 2009 (2), P30CA060553 (2), 2017 (1), 2019 (1), P30CA016672 (1), P30CA093373 (1), R01CA215694 (1), R01CA296813 (1), R01HL153720 (1), R44CA261516 (1), U01EB026412 (1), U10CA021661 (1), U10CA180868 (1)